Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2485 ARTÍCULOS , VIENDO DEL 2056 AL 2070

Electrochemical Technology for the Detection of Tau Proteins as a Biomarker of Alzheimer's Disease in Blood

Wang J, Lu X, He Y.

Biosensors (Basel). 2025 Feb 4;15(2):85. doi: 10.3390/bios15020085.

Early axonal degeneration linked to clinical decline in Alzheimer's disease progression revealed with diffusion MRI

Gong Z, Laporte JP, Guo AY, Bilgel M, Bae J, Fox NY, de Rouen A, Zhang N, Taranath A, de Cabo R, Egan JM, Ferrucci L, Bouhrara M; Alzheimer’s Disease Neuroimaging Initiative.

J Clin Invest. 2025 Nov 27;136(3):e196638. doi: 10.1172/JCI196638. eCollection 2026 Feb 2.

Evaluation of early-phase (18)F-Florbetaben PET as a surrogate biomarker of neurodegeneration: In-depth comparison with (18)F-FDG PET at group and single patient level

Lojo-Ramírez JA, Fernández-Rodríguez P, Guerra-Gómez M, Marín-Cabañas AM, Franco-Macías E, Jiménez-Hoyuela-García JM, García-Solís D.

J Alzheimers Dis. 2025 Jul;106(1):304-316. doi: 10.1177/13872877251340380. Epub 2025 May 8.

Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?

Ricaurte-Fajardo A, Ivanidze J, Zhang D, Mahmud M, Yasen W, Ravdin L, Pahlajani S, Leon M, Nordvig AS, Chiang GC.

AJNR Am J Neuroradiol. 2025 Jul 1;46(7):1439-1445. doi: 10.3174/ajnr.A8654.

The Eye as a Window to Brain Health: Can Retinal Imaging and AI Modeling Predict Alzheimer's Disease?

Awodiya E.

Brain Behav. 2025 Oct;15(10):e70890. doi: 10.1002/brb3.70890.

Traumatic Brain Injury and Alzheimer's Disease Biomarkers: A Systematic Review of Findings from Amyloid and Tau Positron Emission Tomography

Dybing KM, Vetter CJ, Dempsey DA, Chaudhuri S, Saykin AJ, Risacher SL.

J Neurotrauma. 2025 Mar;42(5-6):333-348. doi: 10.1089/neu.2024.0055. Epub 2024 Dec 6.

The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence

Aisen P, Bateman RJ, Crowther D, Cummings J, Dwyer J, Iwatsubo T, Kosco-Vilbois M, McDade E, Mohs R, Scheltens P, Sperling R, Selkoe D.

Alzheimers Dement. 2025 Jan;21(1):e14342. doi: 10.1002/alz.14342. Epub 2024 Nov 13.

Cerebellar atrophy in biologically confirmed Alzheimer's disease: Associations with amyloidopathy measured by cerebrospinal fluid biomarkers

Munoz-Musat E, Le Prince G, Delmaire C, Paquet C.

J Alzheimers Dis. 2025 Dec;108(3):1204-1211. doi: 10.1177/13872877251386085. Epub 2025 Oct 17.

Mass spectrometry-based methods for biofluid biomarkers for progressive diseases: amyloid peptides and dystrophins

Niwa M, Noda K, Kobayashi Y, Kageyama I, Kodama K.

Bioanalysis. 2025 May;17(10):671-680. doi: 10.1080/17576180.2025.2515011. Epub 2025 Jun 4.

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease

Cline EN, Antwi-Berko D, Sundell K, Johnson E, Hyland M, Zhang H, Vanderstichele H, Kaplow J, Dean RA, Stoops E, Vanmechelen E, Koel-Simmelink MJA, Teunissen CE, Sethuraman G, Feaster T, Siemers E, Jerecic J.

J Prev Alzheimers Dis. 2025 Apr;12(4):100082. doi: 10.1016/j.tjpad.2025.100082. Epub 2025 Feb 17.

A neuropathology case report of a woman with Down syndrome who remained cognitively stable: Implications for resilience to neuropathology

Liou JJ, Lou J, Flores-Aguilar L, Nakagiri J, Yong W, Hom CL, Doran EW, Totoiu MO, Lott I, Mapstone M, Keator DB, Brickman AM, Wright ST, Nelson B, Lai F, Xicota L, Dang LT, Li J, Santini T, Mettenburg JM, Ikonomovic MD, Kofler J, Ibrahim T, Head E; Alzheimer Biomarker Consortium ‐ Down Syndrome.

Alzheimers Dement. 2025 Feb;21(2):e14479. doi: 10.1002/alz.14479. Epub 2025 Jan 27.

Mesenchymal Stem Cell-Derived Extracellular Vesicles in Alzheimer's Disease: A Novel Cell-Free Therapeutic Strategy and Diagnostic Biomarker

Wang X, Yang F, Chen P, Yang M, Deng Y, Zhan Z.

Int J Nanomedicine. 2025 Dec 3;20:14375-14391. doi: 10.2147/IJN.S556625. eCollection 2025.

Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study

Decaix T, Mouton-Liger F, Dumurgier J, Cognat E, Vrillon A, Hugon J, Hourregue C, Bouaziz-Amar E, Wallon D, Muraine MQ, Troussière AC, Magnin E, Duron E, Philippi N, Blanc F, Gabelle A, Croisile B, Jager A, Pasquier F, Schraen S, Sayette V, Beaufils É, Miguet-Alfonsi C, Paquet C, Lilamand M.

J Prev Alzheimers Dis. 2025 Jan;12(1):100009. doi: 10.1016/j.tjpad.2024.100009. Epub 2025 Jan 1.

The Evaluation of Clinical Applications for the Detection of the Alzheimer's Disease Biomarker GFAP

Ozcelikay-Akyildiz G, Karadurmus L, Cetinkaya A, Uludag İ, Ozcan B, Unal MA, Sezginturk MK, Ozkan SA.

Crit Rev Anal Chem. 2025;55(8):1690-1701. doi: 10.1080/10408347.2024.2393874. Epub 2024 Aug 23.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias